Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection

Stephen J. Eyre, Donna P Ankerst, John T. Wei, Prakash V. Nair, Meredith M. Regan, Gerrardina Bueti, Jeffrey Tang, Mark A. Rubin, Michael Kearney, Ian M. Thompson, Martin G. Sanda

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: The Prostate Cancer Prevention Trial prostate cancer risk calculator was developed in a clinical trial cohort that does not represent men routinely referred for prostate biopsy. We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice. Materials and Methods: Patients undergoing prostate biopsy by 12 urologists at 5 sites were enrolled in an Early Detection Research Network cohort. The Prostate Cancer Prevention Trial risk calculator was validated by examining area underneath the receiver operating characteristic curve, sensitivity, specificity and calibration comparing observed vs predicted risk of prostate cancer detection. Results: Cancer incidence was greater (43% vs 22%, p = 0.001) in the Early Detection Research Network validation cohort (645) compared to the Prostate Cancer Prevention Trial group (5,519). Early Detection Research Network participants were younger and more racially diverse, and had more abnormal digital rectal examinations and higher prostate specific antigen than Prostate Cancer Prevention Trial participants (all p <0.001). Cancer severity was worse in the Early Detection Research Network cohort than in the Prostate Cancer Prevention Trial (Gleason 7 or higher 60% vs 21%, p <0.001). Nevertheless, the Prostate Cancer Prevention Trial risk calculator was superior to prostate specific antigen alone for predicting cancer in the Early Detection Research Network (AUC 0.691 vs 0.655, p = 0.009) and calibration confirmed that the Prostate Cancer Prevention Trial risk score accurately predicted individual risks in the Early Detection Research Network cohort. Conclusions: Differences between the Early Detection Research Network validation cohort and the Prostate Cancer Prevention Trial cohort underscore the importance of validating calculator performance in the multicenter urology practice setting. Our findings extend the applicability of the Prostate Cancer Prevention Trial calculator for measuring the risk of prostate cancer detection on biopsy to the routine American urology practice setting.

Original languageEnglish (US)
Pages (from-to)2653-2658
Number of pages6
JournalJournal of Urology
Volume182
Issue number6
DOIs
StatePublished - Dec 2009

Fingerprint

Urology
Prostatic Neoplasms
Research
Biopsy
Prostate
Prostate-Specific Antigen
Calibration
Patient Advocacy
Digital Rectal Examination
Early Detection of Cancer
ROC Curve
Area Under Curve
Neoplasms
Clinical Trials

Keywords

  • biological markers
  • clinical trials as topic
  • early detection of cancer
  • mass screening
  • prostate-specific antigen

ASJC Scopus subject areas

  • Urology

Cite this

Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. / Eyre, Stephen J.; Ankerst, Donna P; Wei, John T.; Nair, Prakash V.; Regan, Meredith M.; Bueti, Gerrardina; Tang, Jeffrey; Rubin, Mark A.; Kearney, Michael; Thompson, Ian M.; Sanda, Martin G.

In: Journal of Urology, Vol. 182, No. 6, 12.2009, p. 2653-2658.

Research output: Contribution to journalArticle

Eyre, SJ, Ankerst, DP, Wei, JT, Nair, PV, Regan, MM, Bueti, G, Tang, J, Rubin, MA, Kearney, M, Thompson, IM & Sanda, MG 2009, 'Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection', Journal of Urology, vol. 182, no. 6, pp. 2653-2658. https://doi.org/10.1016/j.juro.2009.08.056
Eyre, Stephen J. ; Ankerst, Donna P ; Wei, John T. ; Nair, Prakash V. ; Regan, Meredith M. ; Bueti, Gerrardina ; Tang, Jeffrey ; Rubin, Mark A. ; Kearney, Michael ; Thompson, Ian M. ; Sanda, Martin G. / Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection. In: Journal of Urology. 2009 ; Vol. 182, No. 6. pp. 2653-2658.
@article{a0b21273df0740f8af2017aa960e5a64,
title = "Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection",
abstract = "Purpose: The Prostate Cancer Prevention Trial prostate cancer risk calculator was developed in a clinical trial cohort that does not represent men routinely referred for prostate biopsy. We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice. Materials and Methods: Patients undergoing prostate biopsy by 12 urologists at 5 sites were enrolled in an Early Detection Research Network cohort. The Prostate Cancer Prevention Trial risk calculator was validated by examining area underneath the receiver operating characteristic curve, sensitivity, specificity and calibration comparing observed vs predicted risk of prostate cancer detection. Results: Cancer incidence was greater (43{\%} vs 22{\%}, p = 0.001) in the Early Detection Research Network validation cohort (645) compared to the Prostate Cancer Prevention Trial group (5,519). Early Detection Research Network participants were younger and more racially diverse, and had more abnormal digital rectal examinations and higher prostate specific antigen than Prostate Cancer Prevention Trial participants (all p <0.001). Cancer severity was worse in the Early Detection Research Network cohort than in the Prostate Cancer Prevention Trial (Gleason 7 or higher 60{\%} vs 21{\%}, p <0.001). Nevertheless, the Prostate Cancer Prevention Trial risk calculator was superior to prostate specific antigen alone for predicting cancer in the Early Detection Research Network (AUC 0.691 vs 0.655, p = 0.009) and calibration confirmed that the Prostate Cancer Prevention Trial risk score accurately predicted individual risks in the Early Detection Research Network cohort. Conclusions: Differences between the Early Detection Research Network validation cohort and the Prostate Cancer Prevention Trial cohort underscore the importance of validating calculator performance in the multicenter urology practice setting. Our findings extend the applicability of the Prostate Cancer Prevention Trial calculator for measuring the risk of prostate cancer detection on biopsy to the routine American urology practice setting.",
keywords = "biological markers, clinical trials as topic, early detection of cancer, mass screening, prostate-specific antigen",
author = "Eyre, {Stephen J.} and Ankerst, {Donna P} and Wei, {John T.} and Nair, {Prakash V.} and Regan, {Meredith M.} and Gerrardina Bueti and Jeffrey Tang and Rubin, {Mark A.} and Michael Kearney and Thompson, {Ian M.} and Sanda, {Martin G.}",
year = "2009",
month = "12",
doi = "10.1016/j.juro.2009.08.056",
language = "English (US)",
volume = "182",
pages = "2653--2658",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection

AU - Eyre, Stephen J.

AU - Ankerst, Donna P

AU - Wei, John T.

AU - Nair, Prakash V.

AU - Regan, Meredith M.

AU - Bueti, Gerrardina

AU - Tang, Jeffrey

AU - Rubin, Mark A.

AU - Kearney, Michael

AU - Thompson, Ian M.

AU - Sanda, Martin G.

PY - 2009/12

Y1 - 2009/12

N2 - Purpose: The Prostate Cancer Prevention Trial prostate cancer risk calculator was developed in a clinical trial cohort that does not represent men routinely referred for prostate biopsy. We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice. Materials and Methods: Patients undergoing prostate biopsy by 12 urologists at 5 sites were enrolled in an Early Detection Research Network cohort. The Prostate Cancer Prevention Trial risk calculator was validated by examining area underneath the receiver operating characteristic curve, sensitivity, specificity and calibration comparing observed vs predicted risk of prostate cancer detection. Results: Cancer incidence was greater (43% vs 22%, p = 0.001) in the Early Detection Research Network validation cohort (645) compared to the Prostate Cancer Prevention Trial group (5,519). Early Detection Research Network participants were younger and more racially diverse, and had more abnormal digital rectal examinations and higher prostate specific antigen than Prostate Cancer Prevention Trial participants (all p <0.001). Cancer severity was worse in the Early Detection Research Network cohort than in the Prostate Cancer Prevention Trial (Gleason 7 or higher 60% vs 21%, p <0.001). Nevertheless, the Prostate Cancer Prevention Trial risk calculator was superior to prostate specific antigen alone for predicting cancer in the Early Detection Research Network (AUC 0.691 vs 0.655, p = 0.009) and calibration confirmed that the Prostate Cancer Prevention Trial risk score accurately predicted individual risks in the Early Detection Research Network cohort. Conclusions: Differences between the Early Detection Research Network validation cohort and the Prostate Cancer Prevention Trial cohort underscore the importance of validating calculator performance in the multicenter urology practice setting. Our findings extend the applicability of the Prostate Cancer Prevention Trial calculator for measuring the risk of prostate cancer detection on biopsy to the routine American urology practice setting.

AB - Purpose: The Prostate Cancer Prevention Trial prostate cancer risk calculator was developed in a clinical trial cohort that does not represent men routinely referred for prostate biopsy. We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice. Materials and Methods: Patients undergoing prostate biopsy by 12 urologists at 5 sites were enrolled in an Early Detection Research Network cohort. The Prostate Cancer Prevention Trial risk calculator was validated by examining area underneath the receiver operating characteristic curve, sensitivity, specificity and calibration comparing observed vs predicted risk of prostate cancer detection. Results: Cancer incidence was greater (43% vs 22%, p = 0.001) in the Early Detection Research Network validation cohort (645) compared to the Prostate Cancer Prevention Trial group (5,519). Early Detection Research Network participants were younger and more racially diverse, and had more abnormal digital rectal examinations and higher prostate specific antigen than Prostate Cancer Prevention Trial participants (all p <0.001). Cancer severity was worse in the Early Detection Research Network cohort than in the Prostate Cancer Prevention Trial (Gleason 7 or higher 60% vs 21%, p <0.001). Nevertheless, the Prostate Cancer Prevention Trial risk calculator was superior to prostate specific antigen alone for predicting cancer in the Early Detection Research Network (AUC 0.691 vs 0.655, p = 0.009) and calibration confirmed that the Prostate Cancer Prevention Trial risk score accurately predicted individual risks in the Early Detection Research Network cohort. Conclusions: Differences between the Early Detection Research Network validation cohort and the Prostate Cancer Prevention Trial cohort underscore the importance of validating calculator performance in the multicenter urology practice setting. Our findings extend the applicability of the Prostate Cancer Prevention Trial calculator for measuring the risk of prostate cancer detection on biopsy to the routine American urology practice setting.

KW - biological markers

KW - clinical trials as topic

KW - early detection of cancer

KW - mass screening

KW - prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=71849102519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849102519&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.08.056

DO - 10.1016/j.juro.2009.08.056

M3 - Article

C2 - 19836788

AN - SCOPUS:71849102519

VL - 182

SP - 2653

EP - 2658

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -